Scientific Research Publishing

Open Journal of Social Sciences, 2026, 14(3), 368-385
https://www.scirp.org/journal/jss
ISSN Online: 2327-5960
ISSN Print: 2327-5952

Comorbid Mental Health Disorders in Autism Spectrum Disorder: Genetic, Neurological, and Environmental Perspectives

Yuanyuan Liu[1,2]

[1]School of Educational Science, Jiangsu Normal University, Xuzhou, China
[2]Zhuxiang School of Futian District, Shenzhen, China
Email: 2693371736@qq.com

How to cite this paper: Liu, Y. Y. (2026). Comorbid Mental Health Disorders in Autism Spectrum Disorder: Genetic, Neurological, and Environmental Perspectives. *Open Journal of Social Sciences, 14,* 368-385.
https://doi.org/10.4236/jss.2026.143021

Received: February 20, 2026
Accepted: March 16, 2026
Published: March 19, 2026

Abstract

Autism Spectrum Disorder (ASD) is one of the most prevalent neurodevelopmental disorders. The co-occurrence of mental health disorders, such as anxiety, depression, and Attention-Deficit/Hyperactivity Disorder (ADHD), in individuals with ASD is alarmingly high and significantly exacerbates the core symptoms of autism, leading to increased functional impairment and reduced quality of life. This review synthesizes current research on the prevalence, genetic and neurological underpinnings, and environmental factors contributing to these comorbidities in ASD. The research explores how shared genetic pathways, including mutations in the SHANK3 and SLC6A4 genes, contribute to the overlapping symptomatology of ASD and its comorbidities. Additionally, it highlights the role of epigenetic mechanisms and gene-environment interactions in modulating the expression of these disorders. Neurological abnormalities, such as altered brain structure and functional connectivity, particularly in the amygdala, prefrontal cortex, and hippocampus, are also discussed as key factors in the manifestation of comorbid mental health conditions. The review underscores the critical importance of early intervention and resilience-building strategies, emphasizing the need for multidisciplinary care models that integrate behavioral therapies, pharmacological treatments, and emerging technologies such as virtual reality and neuromodulation. By addressing the complex interplay between genetic, neurological, and environmental factors, tailored treatment approaches can be developed to improve outcomes and quality of life for individuals with ASD and comorbid mental health disorders.

Keywords

ASD, Comorbid Mental Health, Genetic Pathways, Neurological Factors, Gene-Environment Interactions

1. Introduction

Autism Spectrum Disorder (ASD) affects approximately 1 in 54 children in the United States, making it one of the most prevalent neurodevelopmental disorders (Maenner et al., 2023). In recent years, there has been a growing recognition of the significant impact that comorbid mental health disorders have on individuals with ASD, including conditions such as anxiety, depression, and Attention-Deficit/Hyperactivity Disorder (ADHD) (Barlattani et al., 2023). These comorbidities not only exacerbate the core symptoms of autism but also contribute to increased functional impairment, reduced quality of life, and additional challenges in social integration (Lai & Baron-Cohen, 2015). Furthermore, the presence of these comorbid conditions often complicates the diagnostic process, leading to potential underdiagnosis or misdiagnosis, which can result in inadequate treatment and support (White et al., 2009).

The intersection of ASD and comorbid mental health disorders presents a unique set of challenges for clinicians, researchers, and families (Malik-Soni et al., 2022). As our understanding of autism evolves, it is becoming increasingly clear that a significant proportion of individuals with ASD experience additional mental health challenges, which can amplify their core symptoms and significantly impact their overall functioning (Bradley et al., 2021). This review aims to synthesize current knowledge on the prevalence, underlying mechanisms, and treatment approaches for these comorbidities in individuals with autism, with an emphasis on recent advances in research and clinical practice. By exploring the complex interplay between autism and these mental health disorders, this review seeks to provide a comprehensive overview of the challenges and advances in this field and to highlight the importance of a multidisciplinary approach to treatment that addresses the diverse needs of individuals with ASD.

2. Prevalence of Comorbid Mental Health Disorders in ASD

The prevalence of comorbid mental health disorders in individuals with autism is significantly higher than in the general population (Chien et al., 2021). Various studies report different estimates depending on the sample and methodology used. Research indicates that up to 40% of children and adolescents with ASD experience clinically significant levels of anxiety, a figure derived primarily from clinic-based studies (Kerns & Kendall, 2014; Van et al., 2011). Anxiety disorders are among the most common comorbid conditions in ASD, often manifesting through increased irritability, aggression, and sensory sensitivities, which further complicate social interactions and daily functioning (White et al., 2009).

Depression is another common comorbidity, affecting approximately 20% - 30% of individuals with autism, with symptoms often emerging during adolescence and young adulthood (Gotham et al., 2015). Population-derived cohort studies have reported slightly lower rates in children, underscoring the variability based on sample selection (Simonoff et al., 2008). Recent evidence from a large Brazilian cohort of adults (mean age 32.5 years) confirms that 75.2% experience

at least one co-occurring psychiatric condition, with anxiety (71.8%) and depression (49.7%) being the most prevalent (Paiva et al., 2026). These adult figures are notably higher than those typically reported in pediatric population samples, suggesting an accumulation of comorbidity burden over the lifespan. The onset of depressive symptoms in individuals with ASD is associated with various factors, including social isolation, bullying, and difficulties in adapting to changes in life circumstances (Moseley et al., 2021). Depression in ASD can manifest differently compared to the general population, with symptoms such as anhedonia, low energy, and irritability being more prominent, while traditional signs like sadness and crying may be less evident (Moseley et al., 2011).

ADHD, another common comorbidity, is present in 30% - 50% of individuals with ASD, contributing to challenges in attention, impulse control, and hyperactivity (Reiersen & Todd, 2008; Antshel et al., 2011). The co-occurrence of ADHD and ASD is particularly challenging, as both conditions share overlapping symptoms such as inattention and hyperactivity, making differential diagnosis difficult (Heyman et al., 2022). Moreover, the presence of ADHD can exacerbate the executive functioning deficits commonly seen in ASD, leading to greater difficulties in organizing tasks, regulating emotions, and completing daily activities (Frazier et al., 2012).

These comorbid conditions not only compound the core symptoms of autism but also contribute to increased functional impairment and reduced quality of life (Simonoff et al., 2008). The high prevalence of these disorders underscores the need for comprehensive assessment and targeted interventions that address the full spectrum of an individual's mental health needs. Additionally, the presence of multiple comorbidities can complicate treatment planning, as interventions effective for one condition may not be suitable for another, highlighting the importance of individualized, multidisciplinary care.

3. Genetic Factors Contributing to Comorbidity

Genetic research has provided profound insights into the mechanisms underlying the co-occurrence of ASD and mental health disorders, suggesting that these conditions may share common neurobiological pathways. The identification of shared genetic risk factors has been a pivotal area of study, shedding light on the complex interplay between genetics and mental health in individuals with autism.

3.1. Shared Genetic Pathways

One of the critical areas of focus has been the role of synaptic function in the development of both ASD and comorbid mental health disorders. Variations in genes involved in synaptic function, such as the SHANK3 gene, have been consistently implicated in the development of autism. Evidence from de novo mutation studies and CNV analyses classifies SHANK3 as a high-confidence risk gene for ASD (Leblond et al., 2021). Its link to comorbid anxiety symptoms is understood through its role in cortico-striatal circuits that underlie fear and compulsive

behaviors, although this connection is less frequently confirmed by large-scale GWAS specifically for anxiety disorders (Monteiro & Feng, 2017). A comprehensive gene list update confirms SHANK3 as one of the high-confidence risk genes for ASD and associated neurodevelopmental disorders (Leblond et al., 2021). These findings underscore the importance of synaptic dysfunction as a common underlying mechanism contributing to both ASD and anxiety, highlighting the potential for targeted therapeutic interventions that address synaptic integrity.

Similarly, the SLC6A4 gene, which encodes the serotonin transporter, has been extensively studied in mood disorders. While polymorphisms in SLC6A4 are well-established risk factors for depression in the general population via GWAS (Murphy et al., 2004), their specific contribution to depression in ASD is supported by candidate gene studies but remains an area of active investigation (Shen et al., 2025). This insight opens avenues for exploring serotonergic drugs as potential treatments for comorbid depression in ASD, although the unique neurobiology of autism necessitates careful consideration of drug efficacy and safety.

In addition to specific gene mutations, the study of rare copy number variations (CNVs) and de novo mutations has provided further evidence for the shared genetic architecture between ASD and ADHD. For example, CNVs at the 16p11.2 locus are strongly associated with ASD, while their association with ADHD is less direct but supported by the presence of ADHD symptoms in individuals with these CNVs, suggesting a pleiotropic effect (Niarchou et al., 2019). Similarly, CNVs at 22q11.2 are linked to increased risk for both ASD and ADHD, although the phenotypic expression varies, indicating complex gene-brain-behavior pathways (Sullivan et al., 2012). These regions contain multiple genes involved in brain development, synaptic function, and neural connectivity, further supporting the notion that disruptions in these pathways may underlie the shared etiology of ASD and its comorbid mental health disorders (Geschwind & State, 2015).

Large-scale genome-wide association studies (GWAS) have further elucidated the shared genetic architecture between ASD and ADHD. Cross-disorder GWAS have identified common genetic variants, such as those at the 2p16.3 locus, that show significant association with both ASD and ADHD, contributing to the polygenic risk for these conditions (Cross-Disorder Group of the Psychiatric Genomics Consortium, 2013; Demontis et al., 2019). These findings underscore the polygenic nature of the comorbidity and highlight the role of common variants in addition to rare CNVs. These findings suggest that the cumulative effect of multiple genetic variants may contribute to the shared etiology of ASD and its comorbid mental health disorders, providing a more comprehensive understanding of the genetic underpinnings of these complex conditions.

Furthermore, WGS has enabled the identification of rare de novo mutations that contribute to the risk of both ASD and related psychiatric disorders. De novo mutations, which are genetic changes that occur spontaneously and are not inherited from either parent, have been found to play a significant role in the development of ASD. Recent studies have identified de novo mutations in genes such as

CHD8, SCN2A, and SYNGAP1, which are involved in chromatin remodeling, ion channel function, and synaptic signaling, respectively (Iossifov et al., 2014; Satterstrom et al., 2020). These genes are critical for normal brain development and function, and their disruption may lead to the neurodevelopmental abnormalities observed in ASD and its comorbidities. The identification of these mutations not only enhances our understanding of the genetic basis of ASD but also provides potential targets for the development of novel therapeutic strategies.

3.2. Epigenetic Contributions and Environmental Interactions

Epigenetic research has significantly advanced our understanding of how gene expression is modulated by environmental influences, particularly in the context of Autism Spectrum Disorder (ASD) and its comorbid mental health conditions. Recent studies have demonstrated that epigenetic modifications can significantly impact the expression of genes implicated in ASD and its associated mental health disorders, such as anxiety, depression, and ADHD. For instance, DNA methylation, which involves adding a methyl group to the DNA molecule, can regulate gene expression by silencing or activating specific genes (Dhar et al., 2021). Alterations in DNA methylation patterns have been observed in several key genes involved in synaptic function, immune response, and neurodevelopment in individuals with ASD, suggesting that these epigenetic changes may play a crucial role in the development of comorbid conditions.

One study by Loke et al. (2015) identified distinct DNA methylation patterns in genes associated with synaptic transmission and neuroplasticity, such as the BDNF (brain-derived neurotrophic factor) gene, in individuals with ASD. While these cross-sectional studies in humans suggest a correlation between epigenetic markers and comorbid symptoms, they cannot establish causation. The precise role of these changes in the development of comorbid conditions remains to be definitively proven (Loke et al., 2015; Nardone et al., 2017). Similarly, Nardone et al. (2017) found that histone modifications, which involve chemical changes to the proteins around which DNA is wound, could influence the expression of genes related to immune function and inflammation in ASD. These findings suggest that epigenetic mechanisms may contribute to the immune dysregulation often observed in individuals with autism, which in turn may exacerbate the risk of developing anxiety and depression.

Moreover, the role of non-coding RNAs, such as microRNAs (miRNAs), in regulating gene expression has gained increasing attention in recent years. MiRNAs are small RNA molecules that can modulate gene expression post-transcriptionally by binding to target messenger RNAs (mRNAs) and preventing their translation into proteins. Research has shown that specific miRNAs are dysregulated in individuals with ASD, potentially contributing to the development of comorbid mental health disorders. For example, a study by Mor et al. (2015) identified altered miRNA expression profiles in the prefrontal cortex of individuals with ASD, with several miRNAs implicated in regulating genes involved in synaptic function

and neuronal connectivity. These dysregulated miRNAs may contribute to the neural circuitry abnormalities observed in autism, leading to increased vulnerability to anxiety, depression, and other comorbidities.

3.3. Gene-Environment Interactions in ASD

The interaction between genetic predispositions and environmental factors, often referred to as gene-environment interactions, is a critical determinant of neurodevelopmental outcomes in individuals with ASD. These interactions can influence the severity and expression of ASD symptoms, as well as the likelihood of developing comorbid mental health disorders. For instance, individuals with specific genetic vulnerabilities, such as mutations in the SLC6A4 gene, may be more susceptible to the effects of environmental stressors, leading to an increased risk of developing depression (Caspi et al., 2003). This gene encodes the serotonin transporter, which is crucial for regulating serotonin levels in the brain, a neurotransmitter that plays a key role in mood regulation.

Recent research has highlighted the importance of considering both genetic and environmental factors in understanding the etiology of ASD and its comorbidities. For example, a study by Jansen et al. (2019) found that children with ASD who were exposed to higher levels of prenatal maternal stress exhibited more severe anxiety and depressive symptoms, particularly if they carried specific genetic variants associated with stress sensitivity. These findings suggest that interventions targeting both genetic predispositions and environmental risk factors may be more effective in managing comorbid conditions in individuals with ASD.

Moreover, the concept of "epigenetic plasticity" has emerged as a promising area of research, highlighting the potential for reversing or modifying epigenetic changes through environmental interventions. For example, animal studies have shown that enriching the environment with sensory, social, and cognitive stimuli can lead to positive epigenetic modifications in genes involved in synaptic plasticity and stress response (Murgatroyd et al., 2010). However, a key limitation in translating these findings to clinical practice is that most evidence for the direct modification of epigenetic marks by environmental interventions comes from animal models. Direct evidence that such interventions can reverse adverse epigenetic changes and subsequently reduce psychiatric comorbidity in humans with ASD is currently lacking and requires longitudinal studies.

4. Neurological Factors and Brain Function

Neurological research has increasingly revealed that individuals with Autism Spectrum Disorder (ASD) and comorbid mental health disorders such as anxiety, depression, and Attention-Deficit/Hyperactivity Disorder (ADHD) often exhibit distinct and complex patterns of brain structure and function. These neurobiological abnormalities are believed to underlie many of the behavioral and cognitive symptoms observed in these conditions, providing critical insights into the pathophysiology of ASD and its comorbidities.

4.1. Brain Structure Abnormalities in ASD and Comorbidities

The amygdala, prefrontal cortex, and hippocampus are among the most studied brain regions in ASD research due to their roles in emotion regulation, executive function, and memory. Neuroimaging studies have consistently shown that alterations in these regions are common in individuals with both autism and anxiety or depression (Herrington et al., 2015; Nair et al., 2013). For instance, the amygdala, which is central to processing fear and emotional responses, often exhibits hyperactivity in individuals with ASD, particularly those with comorbid anxiety. This finding is robustly supported by ASD-specific neuroimaging studies that have correlated amygdala hyperarousal with heightened fear responses and social withdrawal in this population (Herrington et al., 2015). This hyperactivity is associated with heightened fear responses, social withdrawal, and difficulties in interpreting social cues, which are hallmark symptoms of anxiety in ASD.

Furthermore, the prefrontal cortex, responsible for higher-order cognitive processes such as planning, decision-making, and emotion regulation, often shows reduced connectivity with other brain regions in individuals with ASD. This reduced connectivity has been linked to difficulties in managing emotions, leading to an increased risk of depression. While this fronto-amygdalar disconnectivity is a well-established model for emotion dysregulation derived from the broader depression literature (Craske et al., 2017), studies in ASD cohorts have similarly found that reduced prefrontal control over the amygdala is associated with greater severity of depressive and anxiety symptoms (Grecucci et al., 2019). Structural imaging studies have also revealed that the prefrontal cortex may be thinner in individuals with ASD and depression, suggesting that neurodevelopmental alterations in this region may contribute to the persistence and severity of depressive symptoms (Pagani et al., 2019).

The hippocampus, another critical region for memory formation and emotional regulation, also shows structural and functional abnormalities in individuals with ASD, particularly those with comorbid anxiety and depression. Reduced hippocampal volume has been observed in individuals with ASD and is associated with difficulties in forming new memories and regulating emotional responses, further exacerbating the challenges faced by individuals with these comorbid conditions (Piras et al., 2014).

4.2. Functional Connectivity and Neurocircuitry in ASD

It should be noted that functional connectivity studies have provided deeper insights into the neurocircuitry underlying ASD and its comorbidities. Functional connectivity refers to the coordinated activity between different brain regions, which is essential for efficient cognitive and emotional functioning. In individuals with ASD, disruptions in functional connectivity between key brain regions have been frequently reported, contributing to the diverse array of cognitive and behavioral challenges associated with the disorder.

One of the most well-documented findings in ASD research is the altered con-

nectivity between the prefrontal cortex and the amygdala. This disrupted connectivity is thought to underlie the emotion regulation difficulties observed in ASD, particularly in those with comorbid anxiety and depression. For example, individuals with ASD often exhibit decreased functional connectivity between these regions during tasks that require emotional regulation, leading to heightened emotional reactivity and difficulties in controlling negative emotions (Grecucci et al., 2019). This altered connectivity may also contribute to the reduced ability to process and respond to social and emotional stimuli, which is a core challenge in ASD.

In the case of ADHD, which is commonly comorbid with ASD, structural and functional abnormalities have been observed in the basal ganglia and frontal lobes. Meta-analyses confirm structural and functional alterations in the basal ganglia and frontal lobes in ASD populations, and these abnormalities are thought to contribute to the overlapping attentional and behavioral challenges seen when ASD and ADHD co-occur (Frazier et al., 2004). These abnormalities are thought to contribute to the attentional and behavioral challenges, such as impulsivity and hyperactivity, that are characteristic of ADHD. Functional neuroimaging studies have further revealed that individuals with ASD and comorbid ADHD often exhibit hypoactivation in the prefrontal cortex during tasks that require sustained attention and inhibitory control (Zhu et al., 2026). This hypoactivation is likely a key factor underlying the executive functioning deficits observed in these individuals, making it difficult for them to focus, plan, and execute tasks effectively.

5. Environmental Factors and the Role of Early Intervention

Environmental factors are increasingly recognized as playing a crucial role in the development, exacerbation, and maintenance of comorbid mental health disorders in individuals with Autism Spectrum Disorder (ASD). These factors, which range from early life stressors to broader socio-economic conditions, interact in complex ways with genetic predispositions, influencing neurodevelopmental outcomes and mental health trajectories. A comprehensive understanding of these interactions is essential for developing effective early interventions that can mitigate the impact of environmental risks and promote better mental health outcomes for individuals with autism.

5.1. The Impact of Adverse Childhood Experiences (ACEs)

Adverse childhood experiences (ACEs) are significant stressors encountered during childhood that include exposure to trauma, abuse, neglect, family dysfunction, and social exclusion. The impact of ACEs on neurodevelopment is profound, particularly in children with ASD, who may have pre-existing vulnerabilities in stress regulation and emotional processing. Research consistently demonstrates a strong link between ACEs and an increased risk of developing comorbid mental health disorders such as anxiety, depression, and post-traumatic stress disorder (PTSD) in individuals with ASD (Green et al., 2016). Children with ASD who experience

ACEs are more likely to exhibit severe behavioral and emotional difficulties, including increased aggression, self-injurious behavior, and heightened sensitivity to environmental stressors (Kerns et al., 2015). These difficulties often persist into adulthood, leading to chronic mental health challenges and impairing overall quality of life.

One of the primary mechanisms through which ACEs exert their influence is the dysregulation of the hypothalamic-pituitary-adrenal (HPA) axis, the body's central stress response system. Chronic activation of the HPA axis, resulting from sustained exposure to stress, can lead to long-term alterations in cortisol levels. These alterations can negatively impact brain regions critical for emotional regulation, such as the amygdala, hippocampus, and prefrontal cortex (Weems, 2017). In individuals with ASD, who may already have atypical neurobiological responses to stress, these changes can significantly increase vulnerability to anxiety and depression.

Additionally, the experience of ACEs can disrupt typical patterns of social and emotional learning, further complicating the development of adaptive coping strategies. Early intervention programs that specifically address the emotional and social needs of children with ASD who have experienced ACEs are crucial. Such programs can provide children with tools to process their experiences, develop resilience, and prevent the long-term mental health consequences often associated with early trauma.

5.2. Socioeconomic Factors and Access to Support

Socioeconomic status (SES) is another critical environmental factor that significantly impacts the mental health outcomes of individuals with ASD. The association between low SES and adverse mental health outcomes is well-documented across various populations, and children with ASD are particularly vulnerable to the compounded effects of poverty, limited access to resources, and social inequalities (Ellemers & Haslam, 2011).

Families with lower SES often face significant barriers in accessing healthcare, educational resources, and social support services, which are crucial for the early identification and treatment of ASD and its comorbidities. Delays in diagnosis and intervention can exacerbate the severity of both core ASD symptoms and associated mental health disorders, making timely access to services a critical factor in improving long-term outcomes (Benevides et al., 2016).

Moreover, the chronic stress associated with financial instability and limited access to resources can have a profound impact on parental mental health. Parents of children with autism frequently experience elevated levels of stress, anxiety, and depression, which can negatively affect their ability to provide consistent care and support (Barker et al., 2011). The bidirectional relationship between parental mental health and child outcomes is well-established, with research indicating that higher levels of parental stress are associated with more severe behavioral and emotional problems in children with ASD (Davis & Carter, 2008).

6. Early Intervention and Resilience Building

Early intervention is widely recognized as a critical strategy for mitigating the impact of environmental risk factors and promoting better mental health outcomes in individuals with ASD. Programs that offer comprehensive family support, behavioral therapies, and social skills training have been shown to be particularly effective in reducing the severity of comorbid mental health symptoms and enhancing the overall quality of life for individuals with autism (Bradshaw et al., 2015).

One of the key goals of early intervention is to build resilience in children with ASD, equipping them with the coping strategies needed to manage stress and navigate social challenges. Resilience can be fostered through interventions that emphasize the development of emotional regulation skills, social competence, and problem-solving abilities (Rao & Beidel, 2009). For example, cognitive-behavioral therapy (CBT) has been adapted for children with ASD to focus on identifying and challenging negative thought patterns, developing effective coping strategies, and enhancing social interactions (Wood et al., 2020). These interventions can help reduce the risk of anxiety and depression by providing children with the tools they need to manage their emotions and behaviors more effectively.

6.1. The Role of Social Support and Community Engagement

The social environment plays a critical role in the mental health of individuals with ASD. Studies have consistently shown that individuals with strong social support networks are less likely to develop anxiety and depression, highlighting the protective effects of social connectedness (Cage et al., 2019). Social support can come from various sources, including family, friends, peers, and community organizations, and can provide emotional, practical, and informational assistance that helps individuals with ASD cope with stress and challenges.

Interventions that promote social inclusion and community engagement are particularly important for improving mental health outcomes in individuals with ASD. Peer mentoring programs, where individuals with ASD are paired with trained peers who provide support and guidance, have been shown to improve social skills, reduce feelings of isolation, and enhance self-esteem (Schall et al., 2012). Similarly, supported employment initiatives that provide job training and workplace accommodations for individuals with ASD can significantly improve their mental health and overall well-being by fostering a sense of purpose and achievement (Bennett & Dukes, 2013).

6.2. Integrated Care Models for Early Identification and Treatment

Access to quality healthcare services is essential for the early identification and treatment of comorbid mental health disorders in individuals with autism. Integrated care models that bring together mental health professionals, primary care providers, and autism specialists have been shown to improve the coordination and effectiveness of care for individuals with ASD and comorbid conditions

(Mandell et al., 2016). These models emphasize the importance of a holistic approach to care that addresses the full range of an individual's needs, including medical, psychological, social, and educational support. For example, the use of multidisciplinary teams that include psychologists, psychiatrists, speech and language therapists, and occupational therapists allows for a comprehensive assessment of the individual's needs and the development of personalized intervention plans. These teams can work collaboratively to address both the core symptoms of ASD and the comorbid mental health disorders, ensuring that treatment is tailored to the individual's unique profile (Reaven et al., 2012).

In addition, the integration of mental health services into primary care settings can facilitate early detection of comorbid conditions, reduce barriers to accessing specialized care, and promote continuity of care (Zerbo et al., 2019). This approach is particularly important for individuals with ASD who may have difficulty navigating complex healthcare systems and who benefit from coordinated care that is easily accessible.

6.3. Evidence-Based Interventions for Comorbid Mental Health Disorders in ASD

Interventions for comorbid mental health disorders in ASD vary in their level of empirical support. Established interventions with support from randomized controlled trials (RCTs) in ASD populations include adapted Cognitive-Behavioral Therapy (CBT) for anxiety. Manualized programs like the Behavioral Interventions for Anxiety in Children with Autism (BIACA) have demonstrated efficacy in reducing anxiety symptoms (Wood et al., 2009; Storch et al., 2013). Pharmacologically, stimulants (e.g., methylphenidate) have RCT evidence for managing ADHD symptoms in individuals with ASD, though they may be associated with increased irritability, necessitating careful monitoring (Soorya et al., 2013). SSRIs for depression and anxiety in ASD show mixed results in controlled trials, and their use requires monitoring for behavioral activation (Vasa et al., 2014).

In contrast, emerging and experimental approaches such as virtual reality (VR) therapy and transcranial magnetic stimulation (TMS) are supported by preliminary studies with smaller sample sizes. While VR shows promise for reducing phobias (Maskey et al., 2019) and TMS for modulating mood (Oberman et al., 2015), they are not yet considered first-line treatments. A practical note for clinicians: Regardless of the intervention, close monitoring for adverse effects, such as increased anxiety, agitation, or changes in sleep patterns, is crucial, as individuals with ASD may exhibit unique sensitivities to both behavioral and pharmacological treatments.

6.4. Advances in Treatment and Clinical Practice

Recent advances in treatment and clinical practice have provided new hope for individuals with autism and comorbid mental health disorders. Pharmacological treatments, such as selective serotonin reuptake inhibitors (SSRIs) and stimulants, have been used to manage symptoms of anxiety, depression, and ADHD in indi-

viduals with autism, although their efficacy and safety profiles require careful consideration due to the unique neurobiology of autism (Soorya et al., 2013). For instance, while SSRIs are commonly prescribed for anxiety and depression, their effects on individuals with ASD can be variable, and some individuals may experience increased agitation or behavioral problems (Vasa et al., 2014).

Behavioral therapies, including cognitive-behavioral therapy (CBT) and mindfulness-based interventions, have shown promise in treating anxiety and depression in individuals with ASD (Wood et al., 2009). These therapies are often adapted to meet the specific needs of individuals with autism, incorporating visual aids, social stories, and other tools to enhance understanding and engagement (Maddox et al., 2017). For example, modified CBT programs that focus on identifying and challenging negative thought patterns, developing coping strategies, and practicing relaxation techniques have been shown to reduce anxiety symptoms in children and adolescents with ASD (Storch et al., 2013).

Furthermore, emerging research on neuromodulation techniques, such as transcranial magnetic stimulation (TMS) and neurofeedback, offers potential new avenues for treatment. These approaches aim to modulate brain activity in targeted regions associated with comorbid mental health disorders, providing a non-invasive option for individuals who may not respond to traditional therapies (D'Agati et al., 2019). For instance, TMS has been used to target the prefrontal cortex in individuals with ASD and comorbid depression, with studies showing reductions in depressive symptoms and improvements in mood regulation (Oberman et al., 2015).

In addition to pharmacological and behavioral interventions, recent advances in technology have opened up new possibilities for the treatment of comorbid mental health disorders in individuals with autism. For example, virtual reality (VR) therapy has been explored as a tool for reducing anxiety and improving social skills in individuals with ASD (Maskey et al., 2019). VR therapy allows individuals to practice social interactions and coping strategies in a safe, controlled environment, with the potential to generalize these skills to real-world situations.

The development of personalized medicine approaches, which tailor treatments to an individual's genetic, neurobiological, and environmental profile, also holds promise for improving outcomes for individuals with ASD and comorbid mental health disorders. For example, pharmacogenetic testing, which examines how an individual's genetic makeup affects their response to medications, could help identify the most effective and least harmful treatments for individuals with autism (Ravyn et al., 2013). Similarly, advancements in neuroimaging and biomarker research could lead to more accurate diagnosis and monitoring of treatment progress in individuals with ASD and comorbid conditions (Ecker et al., 2015).

7. Conclusion

The high prevalence of comorbid mental health disorders in individuals with au-

tism presents significant challenges for diagnosis, treatment, and overall well-being. However, recent advances in genetic, neurological, and environmental research have deepened our understanding of the factors contributing to these comorbidities and paved the way for more effective interventions. By continuing to explore the complex interplay between autism and mental health disorders, and by developing tailored approaches to treatment, we can improve the quality of life for individuals with autism and help them achieve their full potential. Moving forward, a multidisciplinary approach that integrates genetic, neurological, and environmental factors into individualized treatment plans will be crucial for addressing the diverse needs of individuals with ASD and comorbid mental health disorders.

Funding Details

This work was supported by the Postgraduate Research & Practice Innovation Program of Jiangsu Province (Grant No. KYCX24_3000).

Conflicts of Interest

The author reports there are no competing interests to declare.

References

Antshel, K. M., Polacek, C., McMahon, M., Dygert, K., Spenceley, L., Dygert, L. et al. (2011). Comorbid ADHD and Anxiety Affect Social Skills Group Intervention Treatment Efficacy in Children with Autism Spectrum Disorders. *Journal of Developmental & Behavioral Pediatrics, 32,* 439-446. https://doi.org/10.1097/dbp.0b013e318222355d

Barker, E. T., Hartley, S. L., Seltzer, M. M., Floyd, F. J., Greenberg, J. S., & Orsmond, G. I. (2011). Trajectories of Emotional Well-Being in Mothers of Adolescents and Adults with Autism. *Developmental Psychology, 47,* 551-561. https://doi.org/10.1037/a0021268

Barlattani, T., D'Amelio, C., Cavatassi, A., De Luca, D., Di Stefano, R., Di Berardo, A., Pacitti, F. et al. (2023). Autism Spectrum Disorders and Psychiatric Comorbidities: A Narrative Review. *Journal of Psychopathology, 29,* 1-15.

Benevides, T. W., Carretta, H. J., & Lane, S. J. (2016). Unmet Need for Therapy among Children with Autism Spectrum Disorder: Results from the 2005-2006 and 2009-2010 National Survey of Children with Special Health Care Needs. *Maternal and Child Health Journal, 20,* 878-888. https://doi.org/10.1007/s10995-015-1876-x

Bennett, K. D., & Dukes, C. (2013). Employment Instruction for Secondary Students with Autism Spectrum Disorder: A Systematic Review of the Literature. *Education and Training in Autism and Developmental Disabilities, 48,* 67-75. https://doi.org/10.1177/2154164713048001 07

Bradley, L., Shaw, R., Baron-Cohen, S., & Cassidy, S. (2021). Autistic Adults' Experiences of Camouflaging and Its Perceived Impact on Mental Health. *Autism in Adulthood, 3,* 320-329. https://doi.org/10.1089/aut.2020.0071

Bradshaw, J., Steiner, A. M., Gengoux, G., & Koegel, L. K. (2015). Feasibility and Effectiveness of Very Early Intervention for Infants At-Risk for Autism Spectrum Disorder: A Systematic Review. *Journal of Autism and Developmental Disorders, 45,* 778-794. https://doi.org/10.1007/s10803-014-2235-2

Caspi, A., Sugden, K., Moffitt, T. E., Taylor, A., Craig, I. W., Harrington, H. et al. (2003).

Influence of Life Stress on Depression: Moderation by a Polymorphism in the 5-HTT Gene. *Science, 301,* 386-389. https://doi.org/10.1126/science.1083968

Chien, Y. L., Wu, C. S., & Tsai, H. J. (2021). The Comorbidity of Schizophrenia Spectrum and Mood Disorders in Autism Spectrum Disorder. *Autism Research, 14,* 571-581. https://doi.org/10.1002/aur.2451

Craske, M. G., Stein, M. B., Eley, T. C., Milad, M. R., Holmes, A., Rapee, R. M. et al. (2017). Anxiety Disorders. *Nature Reviews Disease Primers, 3,* Article No. 17024. https://doi.org/10.1038/nrdp.2017.24

Cage, E., Cresswell, Z., & Belcher, H. (2019). Understanding the Relationship between Social Support and Mental Health in Autistic Adults. *Journal of Autism and Developmental Disorders, 49,* 3723-3735.

Cross-Disorder Group of the Psychiatric Genomics Consortium (2013). Identification of Risk Loci with Shared Effects on Five Major Psychiatric Disorders: A Genome-Wide Analysis. *The Lancet, 381,* 1371-1379.

D'Agati, E., Curatolo, P., Mazzone, L., & Calabrò, G. E. (2019). Transcranial Magnetic Stimulation in Autism Spectrum Disorder: Neurophysiology, Behavioral, and Therapeutic Implications. *European Journal of Pediatrics, 178,* 69-77.

Davis, N. O., & Carter, A. S. (2008). Parenting Stress in Mothers and Fathers of Toddlers with Autism Spectrum Disorders: Associations with Child Characteristics. *Journal of Autism and Developmental Disorders, 38,* 1278-1291. https://doi.org/10.1007/s10803-007-0512-z

Demontis, D., Walters, R. K., Martin, J., Mattheisen, M., Als, T. D., Agerbo, E. et al. (2019). Discovery of the First Genome-Wide Significant Risk Loci for Attention Deficit/Hyperactivity Disorder. *Nature Genetics, 51,* 63-75. https://doi.org/10.1038/s41588-018-0269-7

Dhar, G. A., Saha, S., Mitra, P., & Nag Chaudhuri, R. (2021). DNA Methylation and Regulation of Gene Expression: Guardian of Our Health. *The Nucleus, 64,* 259-270. https://doi.org/10.1007/s13237-021-00367-y

Ecker, C., Bookheimer, S. Y., & Murphy, D. G. M. (2015). Neuroimaging in Autism Spectrum Disorder: Brain Structure and Function across the Lifespan. *The Lancet Neurology, 14,* 1121-1134. https://doi.org/10.1016/s1474-4422(15)00050-2

Ellemers, N., & Haslam, S. A. (2011). Social Identity Theory. In P. A. M. Van Lange, A. W. Kruglanski, & E. T. Higgins (Eds.), *Handbook of Theories of Social Psychology* (pp. 379-398). Sage Publications Ltd. https://doi.org/10.4135/9781446249222.n45

Frazier, T. W., Demaree, H. A., & Youngstrom, E. A. (2004). Meta-Analysis of Intellectual and Neuropsychological Test Performance in Attention-Deficit/Hyperactivity Disorder. *Neuropsychology, 18,* 543-555. https://doi.org/10.1037/0894-4105.18.3.543

Frazier, T. W., Youngstrom, E. A., Speer, L., Embacher, R., Law, P., Constantino, J. et al. (2012). Validation of Proposed DSM-5 Criteria for Autism Spectrum Disorder. *Journal of the American Academy of Child & Adolescent Psychiatry, 51,* 28-40.e3. https://doi.org/10.1016/j.jaac.2011.09.021

Geschwind, D. H., & State, M. W. (2015). Gene Hunting in Autism Spectrum Disorder: On the Path to Precision Medicine. *The Lancet Neurology, 14,* 1109-1120. https://doi.org/10.1016/s1474-4422(15)00044-7

Gotham, K., Brunwasser, S. M., & Lord, C. (2015). Depressive and Anxiety Symptom Trajectories from School Age through Young Adulthood in Samples with Autism Spectrum Disorder and Developmental Delay. *Journal of the American Academy of Child & Adolescent Psychiatry, 54,* 369-376.e3. https://doi.org/10.1016/j.jaac.2015.02.005

Grecucci, A., Frederickson, J., & Job, R. (2019). Neuropsychotherapy: How Neurosciences Inform Effective Psychotherapy. *Frontiers in Psychology, 10,* Article No. 1622.

Green, J., Leadbitter, K., Kay, C., & Sharma, K. (2016). Autism Spectrum Disorder in Children Adopted after Early Care Breakdown. *Journal of Autism and Developmental Disorders, 46,* 1392-1402. https://doi.org/10.1007/s10803-015-2680-6

Herrington, J. D., Miller, J. S., Pandey, J., Schultz, R. T., & Webb, S. J. (2015). Anxiety and Autism: Towards a Better Understanding of the Relationship. In A. C. Kerns, P. G. Kendall, J. M. Wood, & R. S. Wood (Eds.), *Anxiety in Children and Adolescents with Autism Spectrum Disorder: Evidence-Based Assessment and Treatment* (pp. 1-31). Academic Press.

Heyman, M., Ledoux Galligan, M., Salinas, G. B., Baker, E., Blacher, J., & Stavropoulos, K. (2022). Differential Diagnosis of Autism Spectrum Disorder, Intellectual Disability and Attention-Deficit Hyperactivity Disorder (ADHD). *Advances in Autism, 8,* 89-103. https://doi.org/10.1108/aia-01-2021-0002

Iossifov, I., O'Roak, B. J., Sanders, S. J., Ronemus, M., Krumm, N., Levy, D., & Wigler, M. (2014). The Contribution of de Novo Coding Mutations to Autism Spectrum Disorder. *Nature, 515,* 216-221.

Jansen, P. W., Tiemeier, H., Looman, C. W., Jaddoe, V. W., Hofman, A., Steegers, E. A., & Verhulst, F. C. et al. (2019). Cortisol Reactivity in Childhood and Adolescent Internalizing and Externalizing Psychopathology: A Meta-Analysis. *European Child & Adolescent Psychiatry, 28,* 149-163.

Kerns, C. M., & Kendall, P. C. (2014). The Presentation and Classification of Anxiety in Autism Spectrum Disorder: Where to from Here? *Clinical Psychology: Science and Practice, 19,* 323-347. https://doi.org/10.1111/cpsp.12009

Kerns, C. M., Newschaffer, C. J., & Berkowitz, S. J. (2015). Traumatic Childhood Events and Autism Spectrum Disorder. *Journal of Autism and Developmental Disorders, 45,* 3475-3486. https://doi.org/10.1007/s10803-015-2392-y

Lai, M., & Baron-Cohen, S. (2015). Identifying the Lost Generation of Adults with Autism Spectrum Conditions. *The Lancet Psychiatry, 2,* 1013-1027. https://doi.org/10.1016/s2215-0366(15)00277-1

Leblond, C. S., Le, T., Malesys, S., Cliquet, F., Tabet, A., Delorme, R. et al. (2021). Operative List of Genes Associated with Autism and Neurodevelopmental Disorders Based on Database Review. *Molecular and Cellular Neuroscience, 113,* Article ID: 103623. https://doi.org/10.1016/j.mcn.2021.103623

Loke, Y. J., Hannan, A. J., & Craig, J. M. (2015). The Role of Epigenetic Change in Autism Spectrum Disorders. *Frontiers in Neurology, 6,* Article No. 107. https://doi.org/10.3389/fneur.2015.00107

Maddox, B. B., Miyazaki, Y., & White, S. W. (2017). Long-Term Effects of CBT on Social Impairment in Adolescents with ASD. *Journal of Autism and Developmental Disorders, 47,* 3872-3882. https://doi.org/10.1007/s10803-016-2779-4

Maenner, M. J., Warren, Z., Williams, A. R., Amoakohene, E., Bakian, A. V., Bilder, D. A. et al. (2023). Prevalence and Characteristics of Autism Spectrum Disorder among Children Aged 8 Years—Autism and Developmental Disabilities Monitoring Network, 11 Sites, United States, 2020. *MMWR. Surveillance Summaries, 72,* 1-14. https://doi.org/10.15585/mmwr.ss7202a1

Malik-Soni, N., Shaker, A., Luck, H., Mullin, A. E., Wiley, R. E., Lewis, M. E. S. et al. (2022). Tackling Healthcare Access Barriers for Individuals with Autism from Diagnosis to Adulthood. *Pediatric Research, 91,* 1028-1035. https://doi.org/10.1038/s41390-021-01465-y

Mandell, D. S., Xie, M., Morales, K. H., Lawer, L. J., McCarthy, M., & Marcus, S. C. (2016). The Interplay of Outpatient Services and Psychiatric Hospitalization among Medicaid-Enrolled Children with Autism Spectrum Disorders. *Archives of Pediatrics & Adolescent Medicine, 166,* 68-73. https://doi.org/10.1001/archpediatrics.2011.714

Maskey, M., Lowry, J., Rodgers, J., McConachie, H., & Parr, J. R. (2019). Reducing Specific Phobia/Fear in Young People with Autism Spectrum Disorders (ASD) through a Virtual Reality Environment Intervention. *PLOS ONE, 14,* e0219189.

Monteiro, P., & Feng, G. (2017). SHANK Proteins: Roles at the Synapse and in Autism Spectrum Disorder. *Nature Reviews Neuroscience, 18,* 147-157. https://doi.org/10.1038/nrn.2016.183

Mor, M., Nardone, S., Sams, D. S., & Elliott, E. (2015). Hypomethylation of miR-142 Promoter in Patients with Autism Spectrum Disorders. *Frontiers in Genetics, 6,* Article No. 16.

Moseley, D. S., Tonge, B. J., Brereton, A. V., & Einfeld, S. L. (2011). Psychiatric Comorbidity in Adolescents and Young Adults with Autism. *Journal of Mental Health Research in Intellectual Disabilities, 4,* 229-243. https://doi.org/10.1080/19315864.2011.595535

Moseley, R. L., Turner-Cobb, J. M., Spahr, C. M., Shields, G. S., & Slavich, G. M. (2021). Lifetime and Perceived Stress, Social Support, Loneliness, and Health in Autistic Adults. *Health Psychology, 40,* 556-568. https://doi.org/10.1037/hea0001108

Murgatroyd, C., Wu, Y., Bockmühl, Y., & Spengler, D. (2010). The Role of Epigenetics in Psychosocial Stress and Mental Health. *Neuroendocrinology, 92,* 139-150.

Murphy, D. L., Lerner, A., Rudnick, G., & Lesch, K. P. (2004). Serotonin Transporter: Gene, Genetic Disorders, and Pharmacogenetics. *Molecular Interventions, 4,* 109-123. https://doi.org/10.1124/mi.4.2.8

Nair, A., Trevisan, D. A., & Dapretto, M. (2013). The Neurobiology of Autism: New Pieces of the Puzzle. *Current Opinion in Neurobiology, 23,* 489-495.

Nardone, S., Sams, D. S., Zito, A., Reuveni, E., Elliott, E., & Miller, M. W. (2017). DNA Methylation Analysis of the Autistic Brain Reveals Multiple Dysregulated Biological Pathways. *Translational Psychiatry, 7,* e1129.

Niarchou, M., Martin, J., Thapar, A., Owen, M. J., & van den Bree, M. B. (2019). The Association between 22q11.2 Deletion Syndrome and ADHD Symptoms and Diagnosis: A Systematic Review and Meta-Analysis. *American Journal of Medical Genetics Part A, 179,* 316-326.

Oberman, L. M., Rotenberg, A., & Pascual-Leone, A. (2015). Use of Transcranial Magnetic Stimulation in Autism Spectrum Disorders. *Journal of Autism and Developmental Disorders, 45,* 524-536. https://doi.org/10.1007/s10803-013-1960-2

Pagani, M., Lombardi, F., & Nardo, D. (2019). Functional Magnetic Resonance Imaging in Anxiety and Depression: A Review of the New Methodological Approach Using Machine Learning. *Psychiatria Danubina, 31,* 512-518.

Paiva, J. V. B., Silva, H. d. S. B., Lowenthal, R., & Mecca, T. P. (2026). Co-Occurring Mental Health Disorders in a Brazilian Sample of Adults with Autism Spectrum Disorder: A Focus on Gender Disparities. *Trends in Psychiatry and Psychotherapy.* https://doi.org/10.47626/2237-6089-2025-1229

Piras, F., Cherubini, A., Caltagirone, C., & Spalletta, G. (2014). Metanalysis of Hippocampal Subfields in Neuropsychiatric Disorders: Implications for Neuroimaging Research. *Biological Psychiatry, 75,* 985-992.

Rao, P. A., & Beidel, D. C. (2009). The Impact of Children with High-Functioning Autism on Parental Stress, Sibling Adjustment, and Family Functioning. *Behavior Modification,*

33, 437-451. https://doi.org/10.1177/0145445509336427

Ravyn, D., Ravyn, V., Lowney, R., & von Gruenigen, V. (2013). Pharmacogenetics and Pharmacogenomics in Gynecologic Oncology: The Future of Individualized Patient Care. *Gynecologic Oncology, 128,* 56-64.

Reaven, J., Blakeley-Smith, A., Culhane-Shelburne, K., & Hepburn, S. (2012). Group Cognitive Behavior Therapy for Children with High-Functioning Autism Spectrum Disorders and Anxiety: A Randomized Trial. *Journal of Child Psychology and Psychiatry, 53,* 410-419. https://doi.org/10.1111/j.1469-7610.2011.02486.x

Reiersen, A. M., & Todd, R. D. (2008). Co-Occurrence of ADHD and Autism Spectrum Disorders: Epidemiology and Implications. *Child and Adolescent Psychiatric Clinics of North America, 17,* 299-316.

Satterstrom, F. K., Kosmicki, J. A., Wang, J., Breen, M. S., De Rubeis, S., An, J. et al. (2020). Large-Scale Exome Sequencing Study Implicates both Developmental and Functional Changes in the Neurobiology of Autism. *Cell, 180,* 568-584.e23. https://doi.org/10.1016/j.cell.2019.12.036

Schall, C., Wehman, P., & McDonough, J. L. (2012). Transition from School to Work for Students with Autism Spectrum Disorders: Understanding the Process and Achieving Better Outcomes. *Pediatric Clinics of North America, 59,* 189-202. https://doi.org/10.1016/j.pcl.2011.10.009

Shen, C., Shen, L. M., Qu, F., He, C. Y., Yu, H., Zhang, Z. Y., & Liu, J. (2025). Correlation between Neurotransmitter Transporter Gene Variants and Childhood Autism Spectrum Disorder: A Case-Control Study. *Saudi Journal of Medicine & Medical Sciences, 13,* 173-180. https://doi.org/10.4103/sjmms.sjmms_106_25

Simonoff, E., Pickles, A., Charman, T., Chandler, S., Loucas, T., & Baird, G. (2008). Psychiatric Disorders in Children with Autism Spectrum Disorders: Prevalence, Comorbidity, and Associated Factors in a Population-Derived Sample. *Journal of the American Academy of Child & Adolescent Psychiatry, 47,* 921-929. https://doi.org/10.1097/chi.0b013e318179964f

Soorya, L. V., McDougle, C. J., & Halpern, D. (2013). Psychopharmacologic Interventions for Repetitive Behaviors in Autism Spectrum Disorders. *Child and Adolescent Psychiatric Clinics of North America, 22,* 635-649.

Storch, E. A., Arnold, E. B., Lewin, A. B., Nadeau, J. M., Jones, A. M., De Nadai, A. S. et al. (2013). The Effect of Cognitive-Behavioral Therapy versus Treatment as Usual for Anxiety in Children with Autism Spectrum Disorders: A Randomized, Controlled Trial. *Journal of the American Academy of Child & Adolescent Psychiatry, 52,* 132-142.e2. https://doi.org/10.1016/j.jaac.2012.11.007

Sullivan, P. F., Daly, M. J., & O'Donovan, M. (2012). Genetic Architectures of Psychiatric Disorders: The Emerging Picture and Its Implications. *Nature Reviews Genetics, 13,* 537-551. https://doi.org/10.1038/nrg3240

van Steensel, F. J. A., Bögels, S. M., & Perrin, S. (2011). Anxiety Disorders in Children and Adolescents with Autistic Spectrum Disorders: A Meta-Analysis. *Clinical Child and Family Psychology Review, 14,* 302-317. https://doi.org/10.1007/s10567-011-0097-0

Vasa, R. A., Keefer, A., Reaven, J., South, M., & White, S. W. (2014). Priorities for Advancing Research on Youth with Autism Spectrum Disorder and Co-Occurring Anxiety. *Journal of Autism and Developmental Disorders, 48,* 376-389.

Weems, C. F. (2017). Biological Correlates of Child and Adolescent Fear and Anxiety. In W. K. Silverman, & A. P. Field (Eds.), *Anxiety Disorders in Children and Adolescents: Research, Assessment and Intervention* (pp. 71-96). Cambridge University Press.

White, S. W., Oswald, D., Ollendick, T., & Scahill, L. (2009). Anxiety in Children and Ad-

olescents with Autism Spectrum Disorders. *Clinical Psychology Review, 29,* 216-229. https://doi.org/10.1016/j.cpr.2009.01.003

Wood, J. J., Drahota, A., Sze, K., Har, K., Chiu, A., & Langer, D. A. (2009). Cognitive Behavioral Therapy for Anxiety in Children with Autism Spectrum Disorders: A Randomized, Controlled Trial. *Journal of Child Psychology and Psychiatry, 50,* 224-234. https://doi.org/10.1111/j.1469-7610.2008.01948.x

Wood, J. J., Kendall, P. C., Wood, K. S., Kerns, C. M., Seltzer, M., Small, B. J. et al. (2020). Cognitive Behavioral Treatments for Anxiety in Children with Autism Spectrum Disorder: A Randomized Clinical Trial. *JAMA Psychiatry, 77,* 474-483. https://doi.org/10.1001/jamapsychiatry.2019.4160

Zerbo, O., Qian, Y., Ray, T., Sidney, S., Rich, S., Massolo, M. et al. (2019). Health Care Service Utilization and Cost among Adults with Autism Spectrum Disorders in a U.S. Integrated Health Care System. *Autism in Adulthood, 1,* 27-36. https://doi.org/10.1089/aut.2018.0004

Zhu, C., Bore, M. C., Wang, X., Xu, T., & Feng, T. (2026). Distinct Neurobiological Alterations during Hedonic Experience of Rewards in Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder: Multimodal Evidence from Neuroimaging Meta-analyses. *Molecular Psychiatry*. https://doi.org/10.1038/s41380-026-03495-6